Pfizer $11 Bil. Premium For Pharmacia Calibrated To Merger Savings
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's $11 bil. premium above Pharmacia's recent stock market valuation is a figure calculated from the estimated operating savings in the companies' proposed stock-for-stock transaction
You may also be interested in...
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Pfizer/Pharmacia Merger: Tidbits From The SEC Filings
COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...